Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

The overall Phase 3 trial of TeneX Therapeutics failed, but subgroup analysis indicated a potential therapeutic effect in a specific patient population.

View Source Article ↗

AI CATALYST SCORE50 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

Diagnosed At	Ticker	AI Score	Tier
2026-08-30 19:04:08	TENX	50	Row	View Report →
2026-08-29 12:30:37	TENX	65	Mid	View Report →
2026-08-25 11:48:51	TENX	75	Mid	View Report →

Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

TENX Analysis History (Last 30 Days)